Results 241 to 250 of about 10,558,921 (293)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto +12 more
wiley +1 more source
Trimeric Class I Viral Fusion Protein Vaccine Immunogens Using a Trimeric Autotransporter in a Killed Whole-Cell Bacteria Vaccine Platform: Applications to HIV MPER. [PDF]
VirusesQuintero-Barbosa JS +7 more
europepmc +1 more source
Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. [PDF]
Adv Sci (Weinh)Chen K, Hu Q.
europepmc +1 more source
Designing DNA nanostar hydrogels for sequence-specific degradation and antibody release.
Soft MatterPalombo G +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Designing antibodies as therapeutics
Cell, 2022Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit ...
Paul J. Carter, Arvind Rajpal
openaire +2 more sources
Designer and Catalytic Antibodies
New England Journal of Medicine, 1990A HUMAN being possesses on the order of 1 trillion (1012) B cells, capable of making more than 10 million different antibodies. Tapping this vast resource for clinical purposes is an important but technically challenging endeavor. The production of hybridomas makes it feasible to manufacture large quantities of monoclonal antibodies, and in principle ...
Jane F. Desforges +2 more
openaire +2 more sources
Computational design of antibodies
Current Opinion in Structural Biology, 2018Antibody design aims to create new antibodies with biological activity that can be used in therapy and research. Traditional methods for antibody discovery, such as animal immunization and large-scale library screening, generate antibodies that bind to the target of interest, but do not necessarily have the desired functional effect.
Sharon, Fischman, Yanay, Ofran
openaire +2 more sources
Nature Biotechnology, 1998
Monoclonal antibodies (Mabs) have long been considered a good class of natural drugs, both because they mimic their natural role in the body and because they have no inherent toxicity. Although rodent Mabs are readily generated, their widespread use as therapeutic agents has been hampered because they are recognized as foreign by the patient. Evidently,
T J, Vaughan, J K, Osbourn, P R, Tempest
openaire +2 more sources
Monoclonal antibodies (Mabs) have long been considered a good class of natural drugs, both because they mimic their natural role in the body and because they have no inherent toxicity. Although rodent Mabs are readily generated, their widespread use as therapeutic agents has been hampered because they are recognized as foreign by the patient. Evidently,
T J, Vaughan, J K, Osbourn, P R, Tempest
openaire +2 more sources
Designing antibodies for oncology
Cancer and Metastasis Reviews, 2005The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par
openaire +2 more sources
Phospho-specific antibodies by design
Nature Biotechnology, 2013Antibodies specific to phosphorylated peptides are readily generated through structure-based engineering and in vitro selection.
Oda Stoevesandt, Michael J Taussig
openaire +2 more sources